No Data
Renhe Pharmacy (000650.SZ): The moxifloxacin hydrochloride eye drops have obtained the pharmaceutical registration certificate.
On March 10, Gelonghui reported that Renhe Pharmacy (000650.SZ) announced that its subsidiary Jiangxi Shining Pharmaceutical Co., Ltd. recently received the drug registration certificate for moxifloxacin hydrochloride eye drops approved by the National Medical Products Administration. Moxifloxacin is a broad-spectrum antimicrobial agent with a bactericidal effect belonging to the class of 8-methoxyfluoroquinolones. In vitro, moxifloxacin has shown broad-spectrum antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, acid-fast bacteria, and atypical microorganisms such as mycoplasma, chlamydia, and legionella. Moxifloxacin hydrochloride eye drops are clinically used for sensitive microorganisms (including: Gram-positive bacteria, Gram...
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Renhe Pharmacy (000650.SZ): Some fundraising investment projects are proposed to be delayed.
On December 20, Gelonghui reported that Renhe Pharmacy (000650.SZ) announced the convening of the 23rd temporary meeting of the 9th Board of Directors and the 17th meeting of the 9th Supervisory Board on December 20, 2024, to review and approve the "Proposal on Delaying Some Fundraising Investment Projects." The company agreed to adjust the expected completion dates for the "Digital Health and Disinfection Products Production Line Technology Renovation and Expansion Project" and the "Digital Intelligent Technology Renovation and Expansion Project for Women's Physiological Health Products." After this adjustment, the projects are scheduled to reach their intended usable state by December 31, 2026.
Renhe Pharmacy (000650.SZ): A wholly-owned subsidiary has obtained the registration certificate for Er Dong Tang granule pharmaceutical.
On November 11th, Renhe Pharmacy (000650.SZ) announced that recently, Jiangxi Yaodu Zhangshu Pharmaceutical Co., Ltd., a subsidiary of Renhe Pharmacy Co., Ltd., received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for the Granule of Er Dong Tang. Er Dong Tang is the 80th in the "Catalog of Ancient Classic Formulas (First Batch)" issued by the National Administration of Traditional Chinese Medicine, originating from Volume Three of Qing Dynasty's Cheng Guo Peng's "Medical Insights", composed of Radix Glehniae, Radix Ophiopogonis, Pollen Typhae, Radix Scutellariae, Anemarrhena Rhizome, Lotus Leaf, Ginseng, and Licorice, with the efficacy of moistening the lungs and clearing the stomach. It is used for the treatment of internal heat syndrome, with symptoms such as irritability, unquenchable thirst, frequent urination, and rapid pulse.
Some Investors May Be Willing To Look Past Renhe PharmacyLtd's (SZSE:000650) Soft Earnings
Little Excitement Around Renhe Pharmacy Co.,Ltd's (SZSE:000650) Earnings
Renhe Pharmacy Co., Ltd.'s (SZSE:000650) Share Price Is Matching Sentiment Around Its Earnings